Unlocking the potential of
genomic medicine

2018 News Releases

Date Title
Toggle Summary03/06/2012
MISGAV, Israel & SAN FRANCISCO --(BUSINESS WIRE)--Mar. 6, 2012-- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced
Toggle Summary02/15/2012
MISGAV, Israel & SAN FRANCISCO --(BUSINESS WIRE)--Feb. 15, 2012-- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that
Toggle Summary01/25/2012
MISGAV, Israel & SAN FRANCISCO --(BUSINESS WIRE)--Jan. 25, 2012-- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that
Toggle Summary01/24/2012
Renowned Liver and Kidney Disease Experts Significantly Enhance Advisory in Two Leading Indications for Company’s Protein Production Technology MISGAV, Israel & SAN FRANCISCO --(BUSINESS WIRE)--Jan. 24, 2012-- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer
Toggle Summary01/20/2012
Follows Similar U.S. Patent for Biopump Protein Therapy Technology and Expands Intellectual Property Portfolio MISGAV, Israel & SAN FRANCISCO --(BUSINESS WIRE)--Jan. 20, 2012-- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the developer of a novel technology for the sustained
Toggle Summary01/09/2012
MISGAV, Israel & SAN FRANCISCO --(BUSINESS WIRE)--Jan. 9, 2012-- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that, pursuant to approvals
Toggle Summary11/28/2011
MISGAV, Israel & SAN FRANCISCO, Nov 28, 2011 (BUSINESS WIRE) -- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that
Toggle Summary11/15/2011
Data from Phase I/II Dose-Ranging Study Demonstrate Elevation and Stabilization of Hemoglobin Levels in Anemic Patients for Six to More Than 30 Months MISGAV, Israel & SAN FRANCISCO --(BUSINESS WIRE)--Nov. 15, 2011-- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the
Toggle Summary11/10/2011
MISGAV, Israel & SAN FRANCISCO, Nov 10, 2011 (BUSINESS WIRE) -- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported
Toggle Summary11/09/2011
MISGAV, Israel & SAN FRANCISCO, Nov 09, 2011 (BUSINESS WIRE) -- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today provided a